<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi> is synthesized and released by the pineal gland in a circadian rhythm, and many of its peripheral actions are mediated via membrane MT1 and MT2 receptors </plain></SENT>
<SENT sid="1" pm="."><plain>Apart from its metabolic functions, <z:chebi fb="9" ids="16796">melatonin</z:chebi> is a potent neuroprotective molecule owing to its antioxidative actions </plain></SENT>
<SENT sid="2" pm="."><plain>The roles of MT1 and MT2 in the neuroprotective effects of <z:chebi fb="9" ids="16796">melatonin</z:chebi> and cell signaling after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> remain unknown </plain></SENT>
<SENT sid="3" pm="."><plain>With the use of MT1 and MT2 knockout (mt1/2(-/-) ) mice treated with <z:chebi fb="9" ids="16796">melatonin</z:chebi>, we evaluated brain injury, <z:hpo ids='HP_0000969'>edema</z:hpo> formation, inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) activity, and signaling pathways, including CREB, ATF-1, p21, Jun kinase (JNK)1/2, p38 phosphorylation, resulting from <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury </plain></SENT>
<SENT sid="4" pm="."><plain>We show that the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and <z:hpo ids='HP_0002181'>brain edema</z:hpo> do not differ between mt1/2(-/-) and <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) animals, but <z:chebi fb="9" ids="16796">melatonin</z:chebi> treatment decreases <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in both groups and <z:hpo ids='HP_0002181'>brain edema</z:hpo> in WT animals after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, <z:chebi fb="9" ids="16796">melatonin</z:chebi>'s neuroprotective effect was even more pronounced in mt1/2(-/-) animals compared to that in WT animals </plain></SENT>
<SENT sid="6" pm="."><plain>We also demonstrate that <z:chebi fb="9" ids="16796">melatonin</z:chebi> treatment decreased CREB, ATF-1, and p38 phosphorylation in both mt1/2(-/-) and WT mice, while p21 and JNK1/2 were reduced only in <z:chebi fb="9" ids="16796">melatonin</z:chebi>-treated WT animals in the ischemic hemisphere </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="9" ids="16796">melatonin</z:chebi> treatment lowered iNOS activity only in WT animals </plain></SENT>
<SENT sid="8" pm="."><plain>We provide evidence that the absence of MT1 and MT2 has no unfavorable effect on ischemic brain injury </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, the neuroprotective effects of <z:chebi fb="9" ids="16796">melatonin</z:chebi> appear to be mediated through a mechanism independent of its membrane receptors </plain></SENT>
<SENT sid="10" pm="."><plain>The underlying mechanism(s) should be further studied using selective <z:chebi fb="9" ids="16796">melatonin</z:chebi> receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
</text></document>